Skip to main content

TRPV1 and Synaptic Transmission

Buy Article:

$55.00 plus tax (Refund Policy)

Transient Receptor Potential Vanilloid Type 1 is a prominent “pain” receptor expressed in sensory afferent neurons. TRPV1 on peripheral nerve terminals detects a variety of noxious stimuli generated at sites of injury and inflammation, and in turn, drives the excitation and sensitization of C-fiber neurons. Significantly, TRPV1 is also located on the central terminals of sensory neurons projecting to the spinal cord and brainstem. These TRPV1 channels appear to stimulate the secretion of glutamate. Further, TRPV1 is expressed diffusely in the brain and there is emerging evidence for TRPV1 modulating transmission at various brain synapses. Here we discuss our current understanding of the potential roles for TRPV1 in synaptic transmission.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: (PKC) activation; Brain; CNS; EPSC amplitude; GABAergic transmission; PIP2; PKC stimulation; PLC signaling; Synaptic Transmission; TRPV1; TRPV1 channels; TRPV1 mRNA; amygdala; capsaicin; capsazepine; dopaminergic neurons; eicosanoids; endovanilloids; hippocampal neurons; mEPSCs; neurohypophysis; nociceptive responses; noxious stimuli; pain; periaqueductal gray; presynaptic; presynaptic dopamine receptors; sensory afferent neurons; spinal cord; synaptophysin; tetrodotoxin; vanilloids

Document Type: Research Article

Publication date: 2011-01-01

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more